Gilead submits hep C drug sofosbuvir for FDA approval

04/9/2013 | American City Business Journals · RTT News

Gilead Sciences filed a new drug application with the FDA for sofosbuvir, an oral nucleotide analogue, to treat chronic hepatitis C virus infection. The firm seeks to use sofosbuvir in combination with existing treatments ribavirin and pegylated interferon in treatment-naive patients with genotype 1, 4, 5 and 6 infection. The drug is expected to be approved by year-end or early next year.

View Full Article in:

American City Business Journals · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX